Table 4 Clinicopathologic features of iAMP21 positive adolescent B-ALL without ETV6-RUNX1 fusion

1

15/M

3.1

−8,der(16)t(1;16),−21

5–6

CR^b1 × 9 months

Johnson, 2015 [11]

2

17/M

2.4

Normal Karyotype

>5

Relapsed 58 months after diagnosis following SCT, CR2 × 3 y

Johnson, 2015 [11]

3

20/M

2.2

−13,−14,+21

6–7

CR1 × 30 months

Johnson, 2015 [11]

4

19/M

5.3

del(7)(q11.2)

5–9

CR alive for 2 years

Knez, 2015 [15]

5

13/M

3.7

None

5–10

Unknown

Knez, 2015 [15]

6

15/M

2.1

None

4–8

Relapsed after 7 years of CR

Knez, 2015 [15]

7

13/F

3.0

+X

>5

CR and alive for 3 years

Knez, 2015 [15]

8

15/M

15.8

del(7)(q31)

8

Relapse 2.5 y from diagnosis, CR2 at last chemo block

Haltrich, 2013 [12]

9

14/M

2.2

None

5–10

CR 29 months

Reichard, 2011 [8]

10

15/M

2.0

Not Done

6–8

CR 51 months

Reichard, 2011 [8]

11

13/F

2.8

None

5–10

CR 18 months

Soulier, 2003 [16]

12

17/M

1.0

add(1)(q25)

8

CR 19 months

Soulier, 2003 [16]

13

19/F

10.1

del(7)(p14p21)

6–8

CR 21 months

Soulier, 2003 [16]

14

14/M

2.2

inv(7)(p?15q?21)

5–7

CR 23 months

Soulier, 2003 [16]

15

13/F

3.8

del(7)(q22q35),del(11)(p12)

5

CR 61 months

Soulier, 2003 [16]

16

15/F

9.9

None

4

CR 86 months

Soulier, 2003 [16]

17

15/M

4.3

-Y

4–5

CR 32 months

Soulier, 2003 [16]

18

15/F

NA^a

add(1)(p?),del(6)(q25)

>4

CR 13 months

Soulier, 2003 [16]

19

13/M

7.6

i(9)(q10),−16

4

CR 18 months

Soulier, 2003 [16]

20

13/F

6.6

add(4)(q31),del(7)(q3?2)

5

CR 10 months

Soulier, 2003 [16]

21

14/M

14.5

Normal Karyotype

6–15

CR 48 months

Soulier, 2003 [16]

22

15/F

NA

Normal Karyotype

15–20

Relapsed

Soulier, 2003 [16]